Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 329

Similar articles for PubMed (Select 12639651)

1.

Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia.

Wessells H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L, Herlihy R, Fitch W, Labasky R, Auerbach S, Parra R, Rajfer J, Culbertson J, Lee M, Bach MA, Waldstreicher J; PLESS Study Group.

Urology. 2003 Mar;61(3):579-84.

PMID:
12639651
2.

Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia.

Kaplan SA, Holtgrewe HL, Bruskewitz R, Saltzman B, Mobley D, Narayan P, Lund RH, Weiner S, Wells G, Cook TJ, Meehan A, Waldstreicher J; Proscar Long-Term Efficacy and Safety Study Group.

Urology. 2001 Jun;57(6):1073-7.

PMID:
11377309
3.

Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia.

Lowe FC, McConnell JD, Hudson PB, Romas NA, Boake R, Lieber M, Elhilali M, Geller J, Imperto-McGinely J, Andriole GL, Bruskewitz RC, Walsh PC, Bartsch G, Nacey JN, Shah S, Pappas F, Ko A, Cook T, Stoner E, Waldstreicher J; Finasteride Study Group.

Urology. 2003 Apr;61(4):791-6.

PMID:
12670567
4.

Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.

Roehrborn CG, Bruskewitz R, Nickel JC, McConnell JD, Saltzman B, Gittelman MC, Malek GH, Gottesman JE, Suryawanshi S, Drisko J, Meehan A, Waldstreicher J; Proscar Long-Term Efficacy and Safety Study Group.

J Urol. 2004 Mar;171(3):1194-8.

PMID:
14767299
5.
7.

Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia.

Roehrborn CG, Lee M, Meehan A, Waldstreicher J; PLESS Study Group.

Urology. 2003 Nov;62(5):894-9.

PMID:
14624915
9.

Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.

Bruskewitz R, Girman CJ, Fowler J, Rigby OF, Sullivan M, Bracken RB, Fusilier HA, Kozlowski D, Kantor SD, Johnson EL, Wang DZ, Waldstreicher J.

Urology. 1999 Oct;54(4):670-8.

PMID:
10510926
10.

Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon?

Mondaini N, Gontero P, Giubilei G, Lombardi G, Cai T, Gavazzi A, Bartoletti R.

J Sex Med. 2007 Nov;4(6):1708-12. Epub 2007 Jul 26.

PMID:
17655657
11.

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J.

N Engl J Med. 1998 Feb 26;338(9):557-63.

12.
13.

Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.

Andriole GL, Guess HA, Epstein JI, Wise H, Kadmon D, Crawford ED, Hudson P, Jackson CL, Romas NA, Patterson L, Cook TJ, Waldstreicher J.

Urology. 1998 Aug;52(2):195-201; discussion 201-2.

PMID:
9697781
14.

Proscar: five-year experience.

Moore E, Bracken B, Bremner W, Geller J, Imperato-McGinley J, McConnell J, Roy J, Tenover L, Vaughan D, Pappas F.

Eur Urol. 1995;28(4):304-9. Erratum in: Eur Urol 1996;29(2):234.

PMID:
8575497
15.
16.

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.

Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJ.

N Engl J Med. 1996 Aug 22;335(8):533-9.

17.

Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.

Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittleman M, Morrill B, Wolford ET.

Urology. 2004 Apr;63(4):709-15.

PMID:
15072886
19.

Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group.

Kaplan S, Garvin D, Gilhooly P, Koppel M, Labasky R, Milsten R, Reddy P, Rosenberg S, Sussman D, White C, Lee M, Pappas F, Waldstreicher J.

Urology. 2000 Oct 1;56(4):610-6.

PMID:
11018616
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk